SCIENTIFIC publications

/cun/en/investigacion/publicaciones-cientificas/areaMain/02
  • Tolerogenic dendritic cell-based treatment for multiple sclerosis

    Willekens B# (1,2), Presas-Rodríguez S# (3,4), Mansilla MJ (5,6), Derdelinckx J (1,2), Lee WP (7), Nijs G (7), De Laere M (2), Wens I (2), Cras P (1), Parizel P (8), Van Hecke W (9), Ribbens A (9), Billiet T (9), Adams G (10), Couttenye MM 11, Navarro-Barriuso J (5,6), Teniente-Serra A (5,6), Quirant-Sánchez B (5,6), Lopez-Diaz de Cerio A (12,13), Inogés S (12,13), Prosper F (12,14), Kip A (15), Verheij H (15), Gross CC (16,17), Wiendl H (16,17), Van Ham MS (18,19), Ten Brinke A (18,19), Barriocanal AM (20,21), Massuet-Vilamajó A (22), Hens N (23,24), Berneman Z (2,7), Martínez-Cáceres E (5), Cools N# (25,7), Ramo-Tello C# (26); RESTORE consortium.

    (1) Department of Neurology, University Hospital Antwerp, Edegem, Belgium.
    (2) Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp Faculty of Medicine and Health Sciences, Wilrijk, Belgium.
    (3) Multiple Sclerosis Unit, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
    (4) Department of Medicine, Universitat Autònoma de Barcelona, Cerdanyola del Vallés, Spain.
    (5) Division of Immunology, LCMN, Hospital Universitario Germans Trias i Pujol and Research Institute, Badalona, Spain.
    (6) Department of Cellular Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
    (7) Center for Cell Therapy and Regenerative Medicine, University Hospital Antwerp, Edegem, Belgium.
    (8) Department of Radiology, University Hospital Antwerp, Edegem, Belgium.
    (9) Icometrix NV, Leuven, Belgium.
    (10) C-Clear Partners, Mortsel, Belgium.
    (11) Department of Nephrology, University Hospital Antwerp, Edegem, Belgium.
    (12) Haematology-Cell Therapy Area, clinica universidad de navarra, Pamplona, Spain.
    (13) Immunology and Immunotherapy Department, Clinica Universidad de Navarra, Pamplona, Spain.
    (14) Program of Haematology-Oncology, CIMA, Universidad de Navarra, Pamplona, Spain.
    (15) Lygature, Utrecht, The Netherlands.
    (16) Department of Neurology, University Hospital Munster, Munster, Germany.
    (17) Department of Neurology, University of Munster, Munster, Germany.
    (18) Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
    (19) Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
    (20) Clinical Research Polyvalent Unit, Clinial Trial Unit-Spanish Clinical Research Network, Germans Trias i Pujol Health Sciences Research Institute, Badalona, Spain.
    (21) Department of Pharmacology, Therapeutic and Toxicology, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.
    (22) Institut de Diagnòstic per la Imatge, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
    (23) Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BioStat), Universiteit Hasselt, Hasselt, Belgium.
    (24) Centre for Health Economic Research and Modelling Infectious Diseases, Vaccine & Infectious Disease Institute (VAXINFECTIO) & Center for Statistics, University of Antwerp Faculty of Medicine and Health Sciences, Wilrijk, Belgium.
    (25) Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp Faculty of Medicine and Health Sciences, Wilrijk, Belgium
    (26) Multiple Sclerosis Unit, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    # Contributed equally

    BMJ Open 09 SEPTEMBER 2019

  • Transforming Breast Cancer Together: European elections manifesto 2019 seizing the opportunities for breast cancer patients

    Cardoso F (1), Bușoi CS (2), Cattaneo I (3), Decise D (3), Cardone A (4), Filicevas A (4), Gentile E (5), Wierinck L (5), Knox S (6, Sebastiani S (7), Terrasanta C (7), Ujupan S (8), Ventura R (9), Wilson B (10), Rubio IT (11).

    (1) European School of Oncology (ESO) and Advanced Breast Cancer Global Alliance (ABC Global Alliance), Champalimaud Clinical Centre / Champalimaud Foundation, Lisbon, Portugal.
    (2) Member of the European Parliament, Brussels, Belgium.
    (3) Novartis, Origgio, Italy.
    (4) European Cancer Patient Coalition, Brussels, Belgium.
    (5) Former Member of the European Parliament, Brussels, Belgium.
    (6) Europa Donna- the European Breast Cancer Coalition, Milan, Italy.
    (7) Helsinn Healthcare SA, Lugano, Switzerland.
    (8) Eli Lilly and Company, Brussels, Belgium.
    (9) European School of Oncology (ESO), Advanced Breast Cancer Global Alliance (ABC Global Alliance), Bellinzona, Switzerland.
    (10) Working with Cancer, London, United Kingdom.
    (11) European Society of Breast Cancer Specialists (EUSOMA), European Society of Surgical Oncology (ESSO), Clinica Universidad de Navarra, Madrid, Spain.

    Breast 07 SEPTEMBER 2019

  • Topical Ectoine: A Promising Molecule in the Upper Airways Inflammation-A Systematic Review

    Casale M (1), Moffa A (2), Carbone S (1), Fraccaroli F (1), Costantino A (1), Sabatino L (1), Lopez MA (1), Baptista P (3), Cassano M (2), Rinaldi V (1).

    (1) Unit of Otolaryngology, UOS ORL TI, Campus Bio-Medico University, Rome, Italy.
    (2) Unit of Otolaryngology, University of Foggia, Foggia, Italy.
    (3) Unit of Otolaryngology, Clinica Universitaria de Navarra, Pamplona, Spain.

    Biomed Research International 26 AUGUST 2019

  • The Importance of Gender-Related Anticancer Research on Mitochondrial Regulator Sodium Dichloroacetate in Preclinical Studies In Vivo

    Stakišaitis D (1,2), Juknevičienė M (3), Damanskienė E (3), Valančiūtė A (3), Balnytė I (3), Alonso MM (4).

    (1) Laboratory of Molecular Oncology, National Cancer Institute, 08660 Vilnius, Lithuania.
    (2) Department of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
    (3) Department of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
    (4) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, 55 Pamplona, Spain.

    Cancers 20 AUGUST 2019

  • The immediate efficacy of inhaled nitric oxide treatment in preterm infants with acute respiratory failure during neonatal transport

    Garrido F (1,2), Gonzalez-Caballero JL (3), Lomax R (1), Dady I (1).

    (1) Connect NW, Manchester University NHS Foundation Trust, Newborn Intensive Care Services, St. Mary's Hospital, Oxford Road, Manchester, M13 9WL.
    (2) Clínica Universidad de Navarra, NICU, Madrid, Spain.
    (3) Department of Statistics and Operative Research, University of Cádiz, Facultad de Medicina, Plaza Fragela s/n, Cádiz, Spain.

    Acta Paediatrica 02 AUGUST 2019

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra